

# Association Between Time to Treatment With Endovascular Reperfusion Therapy and Outcomes in Patients With Acute Ischemic Stroke Treated in Clinical Practice

Reza Jahan, MD; Jeffrey L. Saver, MD; Lee H. Schwamm, MD; Gregg C. Fonarow, MD; Li Liang, PhD; Roland A. Matsouaka, PhD; Ying Xian, MD; DaJuanicia N. Holmes, MS; Eric D. Peterson, MD; Dileep Yavagal, MD; Eric E. Smith, MD, MPH

**IMPORTANCE** Randomized clinical trials suggest benefit of endovascular-reperfusion therapy for large vessel occlusion in acute ischemic stroke (AIS) is time dependent, but the extent to which it influences outcome and generalizability to routine clinical practice remains uncertain.

**OBJECTIVE** To characterize the association of speed of treatment with outcome among patients with AIS undergoing endovascular-reperfusion therapy.

**DESIGN, SETTING, AND PARTICIPANTS** Retrospective cohort study using data prospectively collected from January 2015 to December 2016 in the Get With The Guidelines-Stroke nationwide US quality registry, with final follow-up through April 15, 2017. Participants were 6756 patients with anterior circulation large vessel occlusion AIS treated with endovascular-reperfusion therapy with onset-to-puncture time of 8 hours or less.

**EXPOSURES** Onset (last-known well time) to arterial puncture, and hospital arrival to arterial puncture (door-to-puncture time).

**MAIN OUTCOMES AND MEASURES** Substantial reperfusion (modified Thrombolysis in Cerebral Infarction score 2b-3), ambulatory status, global disability (modified Rankin Scale [mRS]) and destination at discharge, symptomatic intracranial hemorrhage (sICH), and in-hospital mortality/hospice discharge.

**RESULTS** Among 6756 patients, the mean (SD) age was 69.5 (14.8) years, 51.2% (3460/6756) were women, and median pretreatment score on the National Institutes of Health Stroke Scale was 17 (IQR, 12-22). Median onset-to-puncture time was 230 minutes (IQR, 170-305) and median door-to-puncture time was 87 minutes (IQR, 62-116), with substantial reperfusion in 85.9% (5433/6324) of patients. Adverse events were sICH in 6.7% (449/6693) of patients and in-hospital mortality/hospice discharge in 19.6% (1326/6756) of patients. At discharge, 36.9% (2132/5783) ambulated independently and 23.0% (1225/5334) had functional independence (mRS 0-2). In onset-to-puncture adjusted analysis, time-outcome relationships were nonlinear with steeper slopes between 30 to 270 minutes than 271 to 480 minutes. In the 30- to 270-minute time frame, faster onset to puncture in 15-minute increments was associated with higher likelihood of achieving independent ambulation at discharge (absolute increase, 1.14% [95% CI, 0.75%-1.53%]), lower in-hospital mortality/hospice discharge (absolute decrease, -0.77% [95% CI, -1.07% to -0.47%]), and lower risk of sICH (absolute decrease, -0.22% [95% CI, -0.40% to -0.03%]). Faster door-to-puncture times were similarly associated with improved outcomes, including in the 30- to 120-minute window, higher likelihood of achieving discharge to home (absolute increase, 2.13% [95% CI, 0.81%-3.44%]) and lower in-hospital mortality/hospice discharge (absolute decrease, -1.48% [95% CI, -2.60% to -0.36%]) for each 15-minute increment.

**CONCLUSIONS AND RELEVANCE** Among patients with AIS due to large vessel occlusion treated in routine clinical practice, shorter time to endovascular-reperfusion therapy was significantly associated with better outcomes. These findings support efforts to reduce time to hospital and endovascular treatment in patients with stroke.

JAMA. 2019;322(3):252-263. doi:10.1001/jama.2019.8286

← Editor's Note [page 263](#)

+ [Video and Supplemental content](#)

+ [CME Quiz at jamanetwork.com/learning](#)

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Reza Jahan, MD, Division of Interventional Neuroradiology, Department of Radiology, 757 Westwood Plaza, Ste 2129, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 ([rjahan@mednet.ucla.edu](mailto:rjahan@mednet.ucla.edu)).

**R**andomized clinical trials (RCTs) have demonstrated the benefit of endovascular-reperfusion therapy over medical therapy among patients with large vessel occlusion in acute ischemic stroke (AIS).<sup>1-6</sup> Several studies suggest a strong time dependency of greater benefit with earlier treatment.<sup>7-10</sup> Existing data regarding the relation of onset-to-treatment time and outcome, however, is limited in precision and representativeness. The pooled analysis of RCTs was of modest size (536 patients undergoing endovascular-reperfusion therapy in 5 trials),<sup>8</sup> and RCT findings may not be directly generalizable to routine clinical practice. Observational studies similarly have been underpowered to delineate time effects with high precision.<sup>1,7,10,11</sup> To address the need for analysis of a large, practice-based data set, the US nationwide Get With the Guidelines-Stroke (GWTG-Stroke) registry was analyzed to determine the association of time to treatment with outcomes from endovascular-reperfusion therapy.

## Methods

GWTG-Stroke is a nationwide registry maintained by the American Heart Association and American Stroke Association to support continuous quality improvement of hospital systems providing care for patients with stroke and transient ischemic attack (TIA).<sup>12,13</sup> Details of the design and conduct of the program have been previously described.<sup>13,14</sup> GWTG-Stroke uses a web-based patient management tool (IQVIA) to collect clinical data on consecutively admitted patients.<sup>13</sup> Hospitals received either approval to enroll patients without individual patient consent under the common rule or a waiver of authorization and exemption from subsequent review by their institutional review board (IRB). The IRB of the data analysis center at Duke University approved the study.

We selected patients with documented anterior circulation large vessel occlusion and interval from last-known well time to arterial puncture time of 8 hours or less. Eligibility criteria are shown in **Figure 1**. The study time period, January 1, 2015, to December 31, 2016, was selected to reflect care occurring after publication of the first positive RCT of endovascular thrombectomy in December 2014.<sup>15</sup> Throughout this time period, endovascular mechanical thrombectomy devices were cleared by the US Food and Drug Administration for use up to 8 hours after onset. In addition, in June 2015, US national practice guidelines recommended endovascular thrombectomy up to 6 hours (high-grade recommendation) and 8 hours (medium-grade recommendation) after onset.<sup>16</sup> Accordingly, the onset-to-puncture criterion of 8 hours or less identified patients treated in accordance with prevailing regulatory and expert consensus guidance.

Analysis was conducted using data from the Comprehensive Stroke Center (CSC) module of the GWTG-Stroke program regarding patients treated between January 1, 2015, and December 31, 2016, with final follow-up through April 15, 2017, (eTable 1 in **Supplement 1**). Admission or medical staff recorded the patient's self-reported race/ethnicity, based on open-ended questions, which was analyzed because prior studies have suggested differences in AIS outcome may be associ-

## Key Points

**Question** What is the relation between time to treatment and outcome from endovascular-recanalization therapy for acute ischemic stroke (AIS)?

**Findings** In this retrospective cohort study of 6756 patients with AIS in a US nationwide clinical registry, earlier onset to treatment was associated with improved outcomes, including, for every 15 minutes faster treatment: higher rates of independent ambulation (absolute increase, 1.14%), functional independence at discharge (absolute increase, 0.91%), and lower mortality/hospice discharge (absolute decrease, -0.77%).

**Meaning** Among patients with AIS treated in routine clinical practice, shorter time to endovascular-recanalization therapy was associated with better outcomes.

ated with race/ethnicity status. Data on hospital-level characteristics were obtained from the American Hospital Association database.


The main clinical outcomes were as follows: (1) discharge to home (vs acute rehabilitation, skilled nursing facility, hospice, death, other); (2) independent ambulation at discharge; (3) freedom from disability (modified Rankin Scale [mRS] score, 0-1) at discharge; and (4) functional independence (mRS score, 0-2) at discharge. The functional independence and freedom from disability outcomes were derived from the mRS, an ordinal measure of global disability with 7 levels ranging from 0 (no symptoms, best) to 5 (severe disability-bedridden) and 6 (dead). Other clinical outcomes were discharge to home or acute rehabilitation, ambulatory with or without assistance at discharge, freedom from disability (mRS score, 0-1) at 3 months, and functional independence (mRS score, 0-2) at 3 months. The main technical outcome was substantial reperfusion, defined as having a modified Thrombolysis in Cerebral Infarction (mTICI) score of 2b to 3 (50%-100% reperfusion).<sup>17</sup> The main adverse event outcomes analyzed were (1) in-hospital mortality/hospice discharge, and (2) symptomatic intracranial hemorrhage (sICH) within 36 hours. Another adverse event outcome analyzed was in-hospital mortality (without discharge to hospice).

Two time intervals were evaluated for relation to each of these outcomes: (1) onset (last-known well) to arterial puncture; and (2) hospital arrival to arterial puncture (door-to-puncture time) (further details in eMethods 1 in **Supplement 1**).

## Statistical Analysis

Percentages were reported for categorical variables and medians and interquartile ranges (IQRs) for continuous variables. The Pearson  $\chi^2$  test and Kruskal-Wallis tests were used to compare variables in the onset-to-puncture and door-to-puncture time epochs. Multivariable logistic regression analysis was performed to assess the association of onset-to-puncture times and door-to-puncture times with clinical and adverse event outcomes. Generalized estimating equations were used in all regression models to account for within-hospital clustering. The multivariable models, detailed in

Figure 1. Flow Diagram Showing Study Population Screening, Eligibility, and Inclusion



<sup>a</sup> Data were for patients with ischemic stroke receiving care between January 1, 2015, and December 31, 2016, with at least 75% of medical history field completion.

<sup>b</sup> Criteria are listed in the order in which applied.

eMethods 2 in [Supplement 1](#), adjusted for 28 patient-level and 9 hospital-level characteristics (eTable 2 in [Supplement 1](#)). The logistic regression model assumes that independent variables have a linear relationship with respect to the prevalence of the dependent variable (ie, the outcome) on the logit scale. All the continuous variables included for adjustment were evaluated for nonlinearity with the outcome, and linear splines were used for those that violated the linearity assumption. The linear splines were placed at the point at which the slope of the straight lines approximating the relationship curve changed.

Rates of missingness of baseline patient characteristics data were low, and for the preponderance of patient-level baseline variables, missing values were imputed to the mode or median as detailed in eResults 1 in [Supplement 1](#). Outcomes with low (0%-15%) data missingness were analyzed with complete

case analysis, and outcomes with higher data missingness were analyzed using inverse probability weighting (detailed in eMethods 2 in [Supplement 1](#)).<sup>18</sup>

The relationships between onset-to-puncture and door-to-puncture times and the binary outcomes were assessed using logistic regression models with restricted cubic splines of onset-to-puncture or door-to-puncture times with knots at the 5th, 35th, 65th, 95th percentiles (eMethods 2 in [Supplement 1](#)). To generate time-benefit curves, outcome-specific predicted probabilities for each value of onset-to-puncture or door-to-puncture time within the observed range were computed while setting all other variables in the model to mean values. Visual assessment and Wald  $\chi^2$  tests were used to assess the linearity of the relationship.

SAS (version 9.4; SAS Institute Inc) software was used for all statistical analyses. All *P* values were 2-sided and statistical significance was defined as a *P* value of less than .05. Adjustments were not made for multiplicity; accordingly, all analyses were considered exploratory. Statistical analyses were not performed on some auxiliary outcomes due to funding constraints. These are reported as *not performed* (eTable 6 and eTable 8 in [Supplement 1](#)).

## Results

During the study period, 191 971 patients with ischemic stroke were entered into the GWTG-Stroke CSC module at hospitals with less than 25% of missing data in medical history items, among whom 14 463 (7.5%) underwent endovascular-reperfusion therapy. Among the 7044 patients meeting target vessel site, treatment time window, and other eligibility criteria for this study, 6756 patients (95.9%) from 231 hospitals had documentation of all study baseline covariates (Figure 1; eTable 2 in [Supplement 1](#)) and constituted the study population. The patient- and hospital-level characteristics of the 288 patients excluded for missing documentation of 1 or more key baseline covariates is included in eTable 3 in [Supplement 1](#). Standardized difference scores indicated the included and excluded groups did not differ in many prognostic variables, including age and baseline score on the National Institutes of Health Stroke Scale (NIHSS), but did differ in others, with the excluded patients less frequently being ambulatory prior to the index stroke and receiving care more often at lower-volume thrombectomy hospitals.

Patient mean (SD) age was 69.5 (14.8) years, 51.2% (3460/6756) were women, and median presenting NIHSS score was 17 (IQR, 12-22). Mode of arrival was by emergency medical services (EMS) transport for 51.1% (3454/6756) of patients, private vehicle for 3.0% (201/6756), and interfacility transfer for 45.7% (3088/6756). Intravenous (IV) recombinant tissue plasminogen activator (rtPA) was administered prior to endovascular-reperfusion therapy in 68.2% (4610/6756) of patients, and the target occlusion site was the internal carotid artery (cervical or intracranial) in 17.0% (1150/6756) and M1 or M2 segments of the middle cerebral artery in 83.0% (5606/6756). Types of endovascular-reperfusion therapy intervention are shown in eResults 2 in [Supplement 1](#). Symptom onset was

witnessed in 67.7% (4572/6756) of patients and unwitnessed in 32.3% (2184/6756) (further details in eFigure 1, eResults 3, eTable 4, and eFigure 2 in [Supplement 1](#)).

The median onset-to-puncture time was 230 minutes (IQR, 170-305) (eFigure 1, [Supplement 1](#)). Across broad onset-to-puncture windows, 6.9% (463/6756) of patients had onset-to-puncture times of 30 to 120 minutes, 47.5% (3207/6756) had 121 to 240 minutes, 33.1% (2235/6756) had 241 to 360 minutes, and 12.6% (851/6756) had onset-to-puncture times of 361 to 480 minutes. Patient-level factors associated with longer onset-to-puncture times included unwitnessed symptom onset (median, 262 minutes [IQR, 200-340]) vs 216 minutes (IQR, 161-286 [ $P < .001$ ]), lower NIHSS score, absence of limb weakness, arrival during off hours (holiday, weekend, or before 7 AM or after 6 PM on Monday-Friday), arrival by interfacility transfer, not having received IV rtPA, and histories of hypertension and of diabetes ([Table 1](#)). Hospital-level factors associated with longer onset-to-puncture time included certification as a CSC, serving as a teaching hospital, and location in the Northeast ([Table 1](#)).

Among all patients, median door-to-puncture time was 87 minutes (IQR, 62-116). Door-to-puncture times were longer in EMS direct-arriving patients than in interfacility transfer patients (100 minutes [IQR, 78-127] vs 65 minutes [IQR, 47-92];  $P < .001$ ) (eFigure 3 in [Supplement 1](#)). Among EMS-arriving patients, patient-level factors associated with longer door-to-puncture times included lower NIHSS score, absence of limb weakness, arrival time during off hours, black or Hispanic race/ethnicity, prior stroke or TIA, and history of hypertension (eTable 5 in [Supplement 1](#)). Hospital-level factors associated with longer door-to-puncture times included smaller facility size, lower annual volume of ischemic stroke admissions, fewer annual performances of endovascular-reperfusion therapy, and fewer annual IV rtPA cases.

Data availability and missingness for baseline covariates and outcomes in study population are detailed in eResults 1 in [Supplement 1](#). For outcomes, complete data were available for in-hospital mortality. Rates of missingness were low for discharge destination (0.3% [18/6756]) and sICH (0.9% [63/6756]), and moderate for substantial reperfusion (6.4% [432/6756]) (defined as modified Thrombolysis in Cerebral Infarction 2b-3; 50%-100% reperfusion)<sup>17</sup> and ambulatory status at discharge (14.4% [973/6756]). The analyses of these outcomes used complete cases. Rates of missingness were higher for discharge mRS (21.1% [1422/6756]) and were substantial for 3-month mRS (44.1% [2976/6756]). Analyses of these outcomes used inverse probability weighting to compensate for patients with missing data on the outcome.<sup>18</sup>

[Table 2](#) and eTable 6 in [Supplement 1](#) show unadjusted event rates and adjusted odds ratios (ORs) for clinical and adverse event outcomes in all patients and those in the 4 onset-to-puncture time windows. Some auxiliary outcomes in eTable 6 ([Supplement 1](#)) did not have statistical analyses performed. Overall, among patients with documented outcomes at discharge, substantial reperfusion was achieved in 85.9% (5433/6324), 27.8% (1876/6756) were discharged to home, 36.9% (2132/5783) were ambulating independently, 23.0% (1225/5334) had functional independence (mRS, 0-2), sICH occurred in 6.7%

(449/6693), and 19.6% (1326/6756) had in-hospital mortality/hospice discharge. In the adjusted analyses, compared with the 6- to 8-hour onset-to-puncture window, patients treated in the 0- to 2-hour time window had significantly better outcomes on 8 of 8 clinical and 2 of 3 adverse event end points. For example, patients in the 0- to 2-hour onset-to-puncture category had higher rates of discharge to home (OR, 2.43 [95% CI, 1.81-3.27]) and functional independence at discharge (OR, 3.45 [95% CI, 2.37-5.02]), and had lower mortality/hospice discharge (OR, 0.51 [95% CI, 0.34-0.75]). Patients treated in the 2- to 4-hour onset-to-puncture window had significantly better outcomes on 6 of 8 clinical end points and 1 of 3 adverse event end points, including higher rates of discharge to home (OR, 1.39 [95% CI, 1.12-1.72]) and functional independence at discharge (OR, 1.69 [95% CI, 1.32-2.17]), but no statistically significant difference in mortality/hospice discharge (OR, 0.92 [95% CI, 0.75-1.12]). Patients treated in the 4- to 6-hour onset-to-puncture window had significantly better outcomes on 1 of 8 clinical end points (functional independence at discharge) and 0 of 3 adverse event end points. eTables 7 and 8 in [Supplement 1](#) show unadjusted rates and adjusted ORs for clinical outcomes and adverse events in EMS-arriving patients in the 5 door-to-puncture time windows, also showing improvement in clinical and adverse event outcomes in earlier time windows. Some auxiliary outcomes in eTable 8 ([Supplement 1](#)) did not have statistical analyses performed.

Continuous time-benefit predicted probability curves, showing the relationship with and without adjustment for baseline characteristics between onset-to-puncture and clinical outcomes and adverse events, are shown in [Figure 2](#) (and eFigure 4, eFigure 5, eTable 9A and eTable 9B in [Supplement 1](#)). For onset-to-puncture, the time-benefit relationship changed around the 240- to the 270-minute time frame. With placement of a spline at 270 minutes, the time-benefit relationships before and after could be modeled as 2 different linear relations, with a steep time-benefit slope in the 0- to 4.5-hour time window and minimal slope in the greater than 4.5- to 8-hour period. Within 270 minutes, all clinical and adverse event outcomes were better with faster treatment. Among every 1000 patients treated, every 15-minute decrease in onset-to-puncture time was associated with 11 (95% CI, 8-15) more patients ambulating independently at discharge (absolute increased likelihood, 1.14% [95% CI, 0.75%-1.53%]), 12 (95% CI, 8-15) more being discharged to home (absolute increased likelihood, 1.15% [95% CI, 0.78%-1.52%]), 10 (95% CI, 6-14) more having freedom from disability at discharge (absolute increased likelihood, 0.98% [95% CI, 0.57%-1.39%]), and 9 (95% CI, 5-14) more having functional independence at discharge (absolute increased likelihood, 0.91% [95% CI, 0.45%-1.36%]) (eTable 9B in [Supplement 1](#)). For adverse events, among every 1000 patients treated, every 15-minute decrease in onset-to-puncture time was associated with 2 (95% CI, 0-4) fewer sICHs (absolute decreased likelihood, -0.22% [95% CI, -0.40% to -0.03%]) and 8 (95% CI, 5-11) fewer deaths prior to discharge or discharge to hospice (absolute decreased likelihood, -0.77% [95% CI, -1.07% to -0.47%]). Time-benefit relationships in analyses confined to patients with witnessed



**Table 1. Patient- and Hospital-Level Characteristics of Patients Treated With Endovascular Reperfusion Therapy, Overall and in Different Onset-to-Puncture Time Windows**

	Onset-to-Puncture Interval Minutes, No. (%)					P Value <sup>a</sup>
	Overall	0-120	121-240	241-360	361-480	
No. of patients	6756	463	3207	2235	851	
Age, mean (SD), y	69.5 (14.8)	69.4 (15.3)	69.9 (14.7)	69.3 (14.8)	68.5 (14.8)	.07
Men	3296 (48.8)	239 (51.6)	1557 (48.6)	1080 (48.3)	420 (49.4)	.60
Women	3460 (51.2)	224 (48.4)	1650 (51.4)	1155 (51.7)	431 (50.6)	
Race/ethnicity						
White, non-Hispanic	4667 (69.1)	287 (62.0)	2237 (69.7)	1562 (69.9)	581 (68.3)	.13
Black, non-Hispanic	1049 (15.5)	86 (18.6)	473 (14.7)	341 (15.3)	149 (17.5)	
Hispanic (all races)	433 (6.4)	36 (7.8)	211 (6.6)	138 (6.2)	48 (5.6)	
Asian, non-Hispanic	178 (2.6)	17 (3.7)	80 (2.5)	57 (2.6)	24 (2.8)	
Other, non-Hispanic <sup>b</sup>	429 (6.35)	37 (7.99)	206 (6.42)	137 (6.13)	49 (5.76)	
Arrival at off hours <sup>c</sup>	3427 (50.7)	107 (23.1)	1540 (48.0)	1271 (56.9)	509 (59.8)	<.001
Arrival by EMS	3454 (51.1)	394 (85.1)	2047 (63.8)	727 (32.5)	286 (33.6)	<.001
Last-known well-to-arrival time, median (IQR), min	141 (62-218)	35 (25-45)	83 (51-139)	208 (159-248)	309 (255-348)	<.001
Received rtPA (at ERT or outside hospital)	4610 (68.2)	350 (75.6)	2430 (75.8)	1495 (66.9)	335 (39.4)	<.0001
Door-to-rtPA (at the ERT hospital) time						
No. of patients	2553	333	1671	495	54	
Median (IQR), min	41 (30-55)	30 (22-40)	41 (31-54)	48 (34-65)	50 (33-60)	<.001
NIHSS score, median (IQR) <sup>d</sup>	17 (12-22)	18 (14-23)	17 (13-22)	17 (12-22)	16 (10-21)	<.001
Severe stroke, NIHSS score >16	4020 (59.5)	303 (65.4)	1972 (61.5)	1297 (58.0)	448 (52.6)	<.001
Absence of limb weakness	388 (5.7)	16 (3.5)	156 (4.9)	164 (7.3)	52 (6.1)	<.001
Medical history						
Hypertension	4850 (71.8)	311 (67.3)	2289 (71.4)	1610 (72.1)	640 (75.2)	.02
Dyslipidemia	2856 (42.3)	203 (44.0)	1356 (42.3)	922 (41.3)	375 (44.1)	.46
Atrial fibrillation/flutter	2393 (35.4)	161 (34.8)	1161 (36.2)	790 (35.4)	281 (33.0)	.38
CAD or prior MI	1665 (24.6)	117 (25.3)	814 (25.4)	520 (23.3)	214 (25.1)	.33
Obesity	1652 (24.5)	103 (22.3)	763 (23.8)	570 (25.5)	216 (25.4)	.30
Diabetes mellitus	1645 (24.4)	97 (21.0)	723 (22.5)	575 (25.7)	250 (29.4)	<.001
Previous stroke/TIA	1517 (22.5)	94 (20.3)	744 (23.2)	494 (22.1)	185 (21.7)	.46
Smoker	1124 (18.1)	72 (15.6)	559 (17.4)	422 (18.9)	171 (20.1)	.10
Heart failure	944 (14.0)	50 (10.9)	462 (14.4)	311 (13.9)	121 (14.2)	.22
Depression	582 (8.6)	44 (9.5)	265 (8.3)	194 (8.7)	79 (9.3)	.69
Drug/alcohol abuse	465 (6.9)	18 (3.9)	237 (7.4)	154 (6.9)	56 (6.6)	.05
Renal insufficiency	393 (5.8)	28 (6.1)	190 (5.9)	121 (5.4)	54 (6.3)	.75
Sleep apnea	263 (3.9)	12 (2.6)	117 (3.6)	90 (4.0)	44 (5.2)	.09
PVD	251 (3.7)	17 (3.7)	118 (3.7)	88 (3.9)	28 (3.3)	.86
Carotid stenosis	186 (2.7)	13 (2.8)	85 (2.6)	59 (2.6)	29 (3.4)	.66
Prosthetic heart valve	144 (2.1)	8 (1.7)	73 (2.3)	40 (1.8)	23 (2.7)	.35
Medication before admission						
Anticoagulant/antiplatelet	3498 (51.8)	236 (51.0)	1661 (51.8)	1170 (52.3)	431 (50.6)	.86
Antihypertensive	3952 (58.5)	233 (50.3)	1872 (58.4)	1338 (59.9)	509 (59.8)	.19
Cholesterol reducer	2803 (41.5)	189 (40.8)	1334 (41.6)	940 (42.1)	340 (40.0)	.75
Antidiabetic	976 (14.4)	54 (11.7)	421 (13.1)	350 (15.7)	151 (17.7)	.005
Hospital size, No. of beds, median (IQR)	572 (425-762)	572 (438-746)	572 (424-739)	595 (429-798)	572 (424-759)	<.001
Hospital region						
West	843 (12.5)	65 (14.0)	380 (11.8)	302 (13.5)	96 (11.3)	.001
South	2943 (43.6)	223 (48.2)	1386 (43.2)	936 (41.9)	398 (46.8)	
Midwest	1526 (22.6)	100 (21.6)	751 (23.4)	520 (23.3)	155 (18.2)	
Northeast	1444 (21.4)	75 (16.2)	690 (21.5)	477 (21.3)	202 (23.7)	

(continued)

**Table 1. Patient- and Hospital-Level Characteristics of Patients Treated With Endovascular Reperfusion Therapy, Overall and in Different Onset-to-Puncture Time Windows (continued)**

	Onset-to-Puncture Interval Minutes, No. (%)					P Value <sup>a</sup>
	Overall	0-120	121-240	241-360	361-480	
Academic hospital	5922 (87.7)	374 (80.1)	2762 (86.1)	2009 (89.9)	777 (91.3)	<.001
Primary stroke center	4714 (69.8)	335 (72.3)	2212 (69.0)	1571 (70.3)	596 (70.0)	.43
Comprehensive stroke center	3334 (49.3)	191 (41.3)	1560 (48.6)	1164 (52.1)	419 (49.2)	<.001
Urban location (vs rural location)	6756 (100)	463 (100)	3207 (100)	2235 (100)	851 (100)	
Ischemic stroke discharges, median (IQR), /y <sup>e</sup>	407 (288-494)	405 (287-513)	407 (287-510)	407 (289-490)	407 (280-482)	.48
rtPA administration, median (IQR), /y <sup>f</sup>	36 (27-50)	36 (27-51)	36 (27-56)	35 (27-50)	36 (27-50)	.008
ERT cases, median (IQR), /y <sup>g</sup>	41 (27-62)	45 (28-61)	41 (27-61)	41 (28-61)	43 (28-69)	.005

Abbreviations: AIS, acute ischemic stroke; Antiplat, antiplatelets; CAD, coronary artery disease; EMS, emergency medical service; ERT, endovascular reperfusion therapy; IQR, interquartile range; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; PVD, peripheral vascular disease; rtPA, recombinant tissue plasminogen activator; TIA, transient ischemic attack.

<sup>a</sup> P values are based on Pearson  $\chi^2$  tests for categorical variables and  $\chi^2$  rank-based group means score statistics (Kruskal-Wallis tests) for continuous/ordinal variables.

<sup>b</sup> Other category indicates American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, and unable to determine (due to patient inability because of stroke and unavailability of family members).

<sup>c</sup> Off hours indicate holidays, weekends, or times before 7 AM and after 6 PM Monday through Friday.

<sup>d</sup> The NIHSS score ranges from 0 to 42 (higher scores indicate greater stroke severity).

<sup>e</sup> Annual volume of ischemic stroke discharges: number of admissions for AIS per year during study period.

<sup>f</sup> Annual volume of rtPA administration: number of admissions in which intravenous rtPA was administered for AIS per year during study period.

<sup>g</sup> Annual volume of ERT cases: number of admissions in which endovascular reperfusion therapy was provided for AIS per year during study period.

stroke onset and confined to patients with unwitnessed stroke onset are shown in eFigure 6 and eTable 10 in Supplement 1.

Continuous time-benefit curves for door-to-puncture time and clinical outcomes and adverse events are shown in Figure 3 (and eFigure 7, eFigure 8, eTable 11A, and eTable 11B in Supplement 1). For door-to-puncture time, there were minor changes in time-benefit relationships for 3 of the 6 clinical and adverse event outcomes around 120 minutes. With placement of a spline at 120 minutes, the time-benefit relationships before and after could be modeled as 2 different linear relations for all outcomes. Within 120 minutes, 5 of 6 clinical and adverse event outcomes significantly improved with treatment acceleration. Among every 1000 patients treated, every 15-minute decrease in door-to-puncture time was associated with 17 (95% CI, 1-34) more patients ambulating independently at discharge (absolute increased likelihood, 1.72% [95% CI, 0.08%-3.37%]), 21 (95% CI, 8-34) more being discharged to home (absolute increased likelihood, 2.13% [95% CI, 0.81%-3.44%]), 18 (95% CI, 4-31) more having freedom from disability at discharge (absolute increased likelihood, 1.78% [95% CI, 0.43%-3.14%]), and 22 (95% CI, 7-37) more having functional independence at discharge (absolute increased likelihood, 2.19% [95% CI, 0.71%-3.66%]). For adverse events, among every 1000 patients treated, every 15-minute faster door-to-puncture time was associated with 15 (95% CI, 4-26) fewer patients dying prior to discharge or discharge to hospice (absolute decreased likelihood, -1.48% [95% CI, -2.60% to -0.36%]), without significant changes in sICH (eTable 11B in Supplement 1).

## Discussion

In this exploratory study of 6756 patients, earlier endovascular reperfusion therapy was significantly associated with better outcomes, including independent ambulation at discharge, dis-

charge to home, functional independence and freedom from disability at discharge and at 3 months, and with lower complications, including in-hospital mortality and sICH. In addition, the pace of the reduction in benefit associated with longer onset-to-puncture time intervals was nonlinear for the preponderance of outcomes, with a more rapid benefit loss in the first 30 to 270 minutes and a slower decline between 271 and 480 minutes after witnessed stroke onset.

These findings are consonant with, and extend, prior investigations of the relation between treatment time and functional outcome from endovascular-reperfusion therapy. Prior studies have shown that earlier treatment was associated with better outcomes but generally have been limited due to restricted entry criteria, modest sample sizes, lack of enrollment of consecutive patients, admixture of treated and untreated patients in the intention-to-treat group, and uncertainty about generalizability of findings to routine practice.<sup>7-10</sup> The population treated in the current study was substantially larger than prior studies and reflects data from a diverse range of hospitals, including majority of certified CSCs in the United States.<sup>19</sup> The magnitude of the onset-to-puncture time-benefit relationship in this study broadly accords with that reported in a smaller nationwide registry study in the Netherlands.<sup>11</sup> With a larger data set, the current study was able to explore nonlinear relationships with the outcomes rather than only linear relationships. The present study also reports the relation of door-to-puncture times and outcomes.

The magnitude of the time-benefit relation observed in this study, while requiring validation in an external data set, is clinically meaningful and emphasizes the importance of policies to accelerate treatment start. The magnitude of the association of faster treatment with improved outcomes exceeds that for start of IV rtPA,<sup>20,21</sup> especially among patients with large vessel occlusion,<sup>22</sup> and supports the adoption by regional systems of acute stroke care of direct routing of likely large

Table 2. Main Clinical Outcomes and Adverse Events of Patients Treated With Endovascular Reperfusion Therapy, Overall and in Different Onset-to-Puncture Time Windows

Outcomes	Unadjusted, No. of Patients/Total No. (%) by Onset-to-Puncture Interval Minutes				Adjusted Odds Ratios Comparing Onset-to-Puncture Interval Minutes, (95% CI), <sup>b</sup>				
	Overall	0-120	121-240	241-360	361-480	P Value <sup>a</sup>	0-120 vs 361-480	121-240 vs 361-480	241-360 vs 361-480
Clinical outcome at discharge									
Discharge to home <sup>c</sup>	1876/6756 (27.8)	186/463 (40.2)	923/3207 (28.8)	559/2235 (25.0)	208/851 (24.4)	<.001	2.43 (1.81-3.27)	1.39 (1.12-1.72)	1.12 (0.91-1.39)
Independent ambulation	2132/5783 (36.9)	206/416 (49.5)	1035/2735 (37.8)	644/1897 (34.0)	247/7735 (33.6)	<.001	2.39 (1.76-3.26)	1.40 (1.10-1.78)	1.13 (0.93-1.39)
Freedom from disability <sup>d</sup>	847/5334 (15.9)	101/368 (27.4)	419/2520 (16.6)	235/1755 (13.4)	92/691 (13.3)	<.001	3.18 (2.15-4.71)	1.64 (1.24-2.17)	1.19 (0.90-1.59)
Functional independence <sup>e</sup>	1225/5334 (23.0)	130/368 (35.3)	585/2520 (23.2)	376/1755 (21.4)	134/691 (19.4)	<.001	3.45 (2.37-5.02)	1.69 (1.32-2.17)	1.39 (1.09-1.79)
Technical outcome									
Substantial reperfusion <sup>f</sup>	5433/6324 (85.9)	384/435 (88.3)	2607/3025 (86.2)	1758/2073 (84.8)	684/791 (86.5)	.21	1.14 (0.78-1.68)	1.02 (0.81-1.29)	0.90 (0.73-1.10)
Adverse event outcome									
Symptomatic intracranial hemorrhage	449/6693 (6.7)	14/460 (3.0)	204/3181 (6.4)	160/2207 (7.2)	71/845 (8.4)	.002	0.35 (0.19-0.67)	0.69 (0.51-0.92)	0.81 (0.59-1.10)
In-hospital mortality/hospice discharge	1326/6756 (19.6)	61/463 (13.2)	643/3207 (20.1)	458/2235 (20.5)	164/851 (19.3)	.003	0.51 (0.34-0.75)	0.92 (0.75-1.12)	1.05 (0.87-1.28)
Calculated using the Pearson $\chi^2$ test.									
<sup>d</sup> Freedom from disability (modified Rankin Scale, 0-1).									
<sup>e</sup> Functional independence (modified Rankin Scale, 0-2).									
<sup>f</sup> Substantial reperfusion (modified Thrombolysis in Cerebral Infarction 2b-3). <sup>17</sup>									

<sup>a</sup> Calculated using the Pearson  $\chi^2$  test.<sup>b</sup> Adjusted variables are listed in table 2 in Supplement 1.<sup>c</sup> Indicates discharge to a private residence (vs discharge to acute rehabilitation, skilled nursing facility, hospice, or death).<sup>d</sup> Freedom from disability (modified Rankin Scale, 0-1).<sup>e</sup> Functional independence (modified Rankin Scale, 0-2).<sup>f</sup> Substantial reperfusion (modified Thrombolysis in Cerebral Infarction 2b-3).<sup>17</sup>


vessel-occlusion patients to thrombectomy-capable stroke centers, provided endovascular hospitals are only modestly more distant than primary stroke centers.<sup>23</sup>

The findings provide novel information regarding the time-benefit curve for endovascular thrombectomy. Prior studies generally assumed a linear decline of benefit, but with the larger cohort in this study, the time-benefit curve was derived in a data-driven manner and showed a nonlinear relationship with rapid loss of benefit from 0.5 to 4 hours, transitioning to slower loss of benefit in the 4.5- to 8-hour onset-to-puncture time window. This shape of the time-benefit curve likely arises, in part, as a result of imaging selection for treatment. The pace of infarct growth varies widely among individual patients.<sup>24-27</sup> Early after onset, both “fast progressors” and “slow progressors” will have small to moderate volumes of infarct core (irreversibly injured tissue), and therefore be judged appropriate for intervention.<sup>28</sup> But later, after onset, fast progressors will have large infarcts and be excluded from intervention. Therefore, the later time windows will have few patients with faster paces of infarct expansion and show an attenuated relation of onset-to-puncture time with outcomes.<sup>29</sup> Recent RCTs in imaging-selected patients, up to 24 hours after last-known well time, have confirmed benefit from endovascular-reperfusion therapy in slowly progressing patients.<sup>6,29</sup> A question for clinicians is the following: at what chronologic time point, after last-known well time, do a substantial proportion of fast progressors reach large cores that limit excellent outcomes, as that would be the demarcation point at which to consider switching from a time-based to a tissue-based patient selection strategy. The current study’s findings suggest that time point may begin as early as 240 to 270 minutes after last-known well time.

Findings from the current study can help inform the selection of treatment speed metrics for quality-improvement programs.<sup>16,30-32</sup> The current study reinforces RCT findings indicating there is no single early door-to-puncture time point at which there is a sudden drop in benefit; rather, there is a continuous decline in benefit throughout the first 180 minutes. However, quality measures are generally constructed as the proportion of patients in whom a target is achieved. A successful precedent is the door-to-treatment time for IV rtPA in AIS, for which an initial national target was set at increasing achievement within 60 minutes from 25% to 50% of patients.<sup>33</sup> Based on the 25th percentiles in the current study, potential national quality target door-to-puncture times could be selected to be within 75 minutes in EMS direct-arriving patients and within 45 minutes in transfer patients.

Faster endovascular-reperfusion therapy treatment requires faster activation of EMS by witnesses, by prehospital personnel efficiently routing patients to thrombectomy-capable hospitals and with rapid triage and treatment of patients within systems of care. These results identify several targets to reduce treatment delays.<sup>34</sup> Patients arriving at the hospital in off hours had delayed treatment times; improved staffing during these periods may reduce this disparity. Expanding availability of endovascular thrombectomy to more hospitals is advantageous to provide rapid access for more patients, though higher case-volume hospitals have more efficient door-to-puncture times,<sup>34</sup> suggesting the desirability of avoiding

**Figure 2. Changes in Main Clinical Outcomes and Adverse Events With Continuous Variation in Onset-to-Puncture Time, Adjusted Analysis**




Onset time was defined as last-known well time. Relationships between onset-to-puncture times and the binary outcomes were assessed using logistic regression models with restricted cubic splines with knots at the 5th, 35th, 65th, and 95th percentiles. Curves (blue shading indicates 95% CIs) show the adjusted predicted outcome rate for a hypothetical patient with mean values

for baseline characteristics, for symptom onset to arterial puncture times as a continuous variable, and 6 main clinical outcomes: (A), independent ambulation at discharge; (B), discharge to home; (C), functional independence (mRS, 0-2) at discharge; (D), freedom from disability (mRS, 0-1) at discharge; (E), in-hospital mortality; and (F), symptomatic intracranial hemorrhage.



**Figure 3. Changes in Main Clinical Outcomes and Adverse Events With Continuous Variation in Door-to-Puncture Time, Adjusted Analysis**



Relationships between door-to-puncture times and the binary outcomes were assessed using logistic regression models with restricted cubic splines with knots at the 5th, 35th, 65th, and 95th percentiles. These door-to-puncture analyses indicate patients who arrived direct via emergency medical services transport, not interfacility transfer. Curves (blue shading indicates 95% CIs) show the adjusted predicted outcome rate for a hypothetical patient with

mean values for baseline characteristics, for door-to-puncture times as a continuous variable, and 6 main clinical outcomes: (A), independent ambulation at discharge; (B), discharge to home; (C), functional independence (mRS, 0-2) at discharge; (D), freedom from disability (mRS, 0-1) at discharge; (E), in-hospital mortality; and (F), symptomatic intracranial hemorrhage.

duplicate hospital services when not mandated by geographic distribution. Certification as a stroke center was associated with shorter treatment times, suggesting beneficial effect of continuous quality improvement required by certifying bodies.

### Limitations

This study has several limitations. First, the data reported depends on the accuracy and completeness of abstraction from the medical record. To optimize data quality, the GWTG-Stroke program includes detailed training of site chart abstractors, standardized case definitions and coding instructions, pre-defined logic and range checks on data fields at data entry, audit trails, and regular data quality reports for all sites.

Second, data missingness was present for some outcomes, particularly for the mRS at discharge and at 3 months poststroke. However, complete or only minimal missing data were present for the preponderance of outcomes. Propensity weighting was employed to mitigate potential bias due to missing data, and indeed, time-benefit patterns for outcomes with low and higher missing data were very similar. In addition, prior studies have demonstrated that functional outcomes at discharge correlate highly with 3-month outcomes.<sup>35,36</sup> Data missingness for some key baseline covariates led to exclusion of some otherwise eligible patients (4.1%) from the analysis. The included and excluded groups did not differ in many prognostic variables, including the 2 most important for stroke, age, and baseline NIHSS score. The included and excluded groups did differ in other baseline prognostic variables, including the excluded patients less frequently being ambulatory prior to the index stroke and receiving care more often at lower-volume thrombectomy hospitals.

Third, this study analyzed time until arterial puncture rather than time until achievement of substantial reperfusion. The latter time point corresponds more closely with total ischemia time, the underlying determinant of outcome. Arterial puncture time was analyzed because pilot field testing by

the Joint Commission determined that treating teams were not documenting reperfusion times with high reliability. In the future, with intensified quality-improvement efforts, reperfusion times may be better documented and analyzable. However, prior studies have found that puncture-to-reperfusion times for AIS account for a small and predictable proportion of onset-to-reperfusion times, so event-to-puncture times track very closely with event-to-reperfusion times.<sup>37</sup>

Fourth, the GWTG-Stroke database did not collect information regarding which patients had or did not have advanced physiological imaging (perfusion computed tomography [CT], dynamic 3D CT angiography, perfusion-diffusion magnetic resonance imaging) performed and treatment decisions based on tissue state rather than chronologic time. Physiological imaging, if performed, is unlikely to have influenced time-benefit curves substantially in the 30- to 270-minute onset-to-puncture window, when it shows favorable penumbral profiles in the great preponderance of patients, but it may have attenuated the time-benefit relationship in the 271- to 480-minute window.<sup>24</sup>

Fifth, the time-benefit outcome curves presented were derived from the full study population and analyzed in an exploratory manner without adjustment for multiplicity. They require validation in an external population before reaching conclusions about robustness. Sixth, residual measured and unmeasured confounding may have influenced study findings.

## Conclusions

Among patients with large vessel occlusion AIS treated in routine clinical practice, shorter time to endovascular reperfusion therapy was significantly associated with better outcomes. These findings support efforts to reduce time to hospital and endovascular treatment in patients with stroke.

### ARTICLE INFORMATION

**Accepted for Publication:** June 11, 2019.

**Author Affiliations:** Division of Interventional Neuroradiology, David Geffen School of Medicine, University of California, Los Angeles (Jahan); Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (Saver); Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts (Schwamm); Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles (Fonarow); Duke Clinical Research Center, Durham, North Carolina (Liang, Xian, Holmes, Peterson); Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina (Matsouaka); Department of Neurology, University of Miami Health System, Miami, Florida (Yavagal); Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada (Smith).

**Author Contributions:** Drs Jahan and Saver had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Jahan and Saver contributed equally to the study.

**Concept and design:** Jahan, Saver, Fonarow, Xian, Yavagal, Smith.

**Acquisition, analysis, or interpretation of data:**

Jahan, Saver, Schwamm, Fonarow, Liang, Matsouaka, Xian, Holmes, Peterson, Smith.

**Drafting of the manuscript:** Jahan, Saver.

**Critical revision of the manuscript for important intellectual content:** Jahan, Schwamm, Fonarow, Liang, Matsouaka, Xian, Holmes, Peterson, Yavagal, Smith.

**Statistical analysis:** Saver, Liang, Matsouaka, Xian, Holmes.

**Obtained funding:** Saver, Fonarow.

**Administrative, technical, or material support:** Saver, Fonarow, Smith.

**Supervision:** Jahan, Schwamm, Fonarow.

**Conflict of Interest Disclosures:** Dr Jahan reports being a consultant for Medtronic Neurovascular, Balt USA, BlackSwan Vascular Inc, and Viz.ai outside the submitted work. Dr Saver reports being an employee of the University of California, which has patent rights in retrieval devices for stroke. Dr Saver reports serving as an unpaid site investigator in multicenter trials sponsored by Medtronic, Stryker, Johnson & Johnson, and Boehringer Ingelheim

(prevention only), for which the University of California Regents received payments on the basis of clinical trial contracts for the number of patients enrolled; receipt of contracted hourly payments for services as a scientific consultant advising on rigorous trial design and conduct to Medtronic, Stryker, Johnson & Johnson, and Boehringer Ingelheim (prevention only); and contracted stock options for services as a scientific consultant advising on rigorous trial design and conduct to Rapid Medical. Dr Schwamm reports serving as chair of the stroke clinical work group of Get With The Guidelines-Stroke (GWTG-Stroke) and as a stroke system consultant to the Massachusetts Department of Public Health for the Paul Coverdell National Acute Stroke Registry; and receipt of research support from the Patient-Centered Outcome Research Institute, National Institute of Neurological Disorders and Stroke, and Genentech; and serving as a scientific consultant regarding trial design and conduct to Penumbra (data and safety monitoring committee [Separator 3D and MIND trial]), Genentech (steering committee [TIMELESS trial]), and Medtronic (Victory AF, REACT AF and Stroke AF trials). Dr Fonarow reported serving on the GWTG steering committee; receiving grant

funding from the Patient-Centered Outcome Research Institute; being an employee of the University of California, which has a patent on an endovascular therapy device; and serving as a consultant for Janssen. Dr Xian reported receipt of grants from Genentech during the conduct of the study and grants from Genentech outside the submitted work. Dr Peterson reported receipt of grants from Genentech and Regeneron; and grants and personal fees from Sanofi, AstraZenica, Amarin, and Amgen outside the submitted work. Dr Yavagal reported receipt of personal fees from Medtronic, Cerenovus/Johnson & Johnson, Rapid Medical, and Neuralanalytics outside the submitted work. Dr Smith reports serving as consultant for Alnylam Pharmaceuticals and Portola Pharmaceuticals; being a member of the GWTG steering committee; and serving on a data and safety monitoring board for Massachusetts General Hospital. No additional disclosures were reported.

**Funding/Support:** The GWTG-Stroke program is provided by the American Heart Association (AHA)/American Stroke Association. GWTG-Stroke is sponsored, in part, by Medtronic and has been funded in the past through support from Boehringer Ingelheim, Merck, Bristol-Myers Squibb/Sanofi Pharmaceutical Partnership, Janssen Pharmaceutical Companies of Johnson & Johnson and the AHA Pharmaceutical Roundtable.

**Role of the Funder/Sponsor:** The AHA had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Disclaimer:** Drs Saver and Peterson, associate editors for JAMA, were not involved in the editorial review of or decision to publish this article.

## REFERENCES

- Goyal M, Menon BK, van Zwam WH, et al; HERMES Collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet*. 2016;387(10029):1723-1731. doi:10.1016/S0140-6736(16)00163-X
- Bracard S, Ducrocq X, Mas JL, et al; THRACE Investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol*. 2016;15(11):1138-1147. doi:10.1016/S1474-4422(16)30177-6
- Mocco J, Zaidat OO, von Kummer R, et al; THERAPY Trial Investigators. Aspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone. *Stroke*. 2016;47(9):2331-2338. doi:10.1161/STROKEAHA.116.013372
- Muir KW, Ford GA, Messow CM, et al; PISTE Investigators. Endovascular therapy for acute ischaemic stroke: the Pragmatic Ischaemic Stroke Thrombectomy Evaluation (PISTE) randomised, controlled trial. *J Neurol Neurosurg Psychiatry*. 2017;88(1):38-44. doi:10.1136/jnnp-2016-314117
- Albers GW, Marks MP, Kemp S, et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med*. 2018;378(8):708-718. doi:10.1056/NEJMoa1713973
- Nogueira RG, Jadhav AP, Haussen DC, et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. *N Engl J Med*. 2018;378(1):11-21. doi:10.1056/NEJMoa1706442
- Mueller-Kronast NH, Zaidat OO, Froehler MT, et al; STRATIS Investigators. Systematic evaluation of patients treated with neurothrombectomy devices for acute ischemic stroke: primary results of the STRATIS registry. *Stroke*. 2017;48(10):2760-2768. doi:10.1161/STROKEAHA.117.016456
- Saver JL, Goyal M, van der Lugt A, et al; HERMES Collaborators. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. *JAMA*. 2016;316(12):1279-1288. doi:10.1001/jama.2016.13647
- Sheth SA, Jahan R, Gralla J, et al; SWIFT-STAR Trialists. Time to endovascular reperfusion and degree of disability in acute stroke. *Ann Neurol*. 2015;78(4):584-593. doi:10.1002/ana.24474
- Zaidat OO, Castonguay AC, Nogueira RG, et al. TREVO stent-retriever mechanical thrombectomy for acute ischemic stroke secondary to large vessel occlusion registry. *J Neurointerv Surg*. 2018;10(6):516-524. doi:10.1136/neurintsurg-2017-013328
- Mulder MJHL, Jansen IGH, Goldhoorn RB, et al; MR CLEAN Registry Investigators. Time to endovascular treatment and outcome in acute ischemic stroke: MR CLEAN registry results. *Circulation*. 2018;138(3):232-240. doi:10.1161/CIRCULATIONAHA.117.032600
- LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get With The Guidelines" program. *Arch Intern Med*. 2008;168(4):411-417. doi:10.1001/archinternmed.2007.101
- Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. *Circulation*. 2009;119(1):107-115. doi:10.1161/CIRCULATIONAHA.108.783688
- Ormseth CH, Sheth KN, Saver JL, Fonarow GC, Schwamm LH. The American Heart Association's Get With the Guidelines (GWTG)-Stroke development and impact on stroke care. *Stroke Vasc Neurol*. 2017;2(2):94-105. doi:10.1136/svn-2017-000092
- Berkhemer OA, Fransen PS, Beumer D, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med*. 2015;372(1):11-20. doi:10.1056/NEJMoa1411587
- Powers WJ, Rabinstein AA, Ackerson T, et al; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. *Stroke*. 2018;49(3):e46-e110. doi:10.1161/STR.0000000000000158
- Zaidat OO, Yoo AJ, Khatri P, et al; Cerebral Angiographic Revascularization Grading (CARG) Collaborators; STIR Revascularization Working Group; STIR Thrombolysis in Cerebral Infarction (TICI) Task Force. Recommendations on angiographic revascularization grading standards for acute ischemic stroke: a consensus statement. *Stroke*. 2013;44(9):2650-2663. doi:10.1161/STROKEAHA.113.001972
- Seaman SR, White IR. Review of inverse probability weighting for dealing with missing data. *Stat Methods Med Res*. 2013;22(3):278-295. doi:10.1177/0962280210395740
- Schieb LJ, Casper ML, George MG. Mapping primary and comprehensive stroke centers by certification organization. *Circ Cardiovasc Qual Outcomes*. 2015;8(6)(suppl 3):S193-S194. doi:10.1161/CIRCOUTCOMES.115.002082
- Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. *JAMA*. 2013;309(23):2480-2488. doi:10.1001/jama.2013.6959
- Kim JT, Fonarow GC, Smith EE, et al. Treatment with tissue plasminogen activator in the golden hour and the shape of the 4.5-hour time-benefit curve in the national United States Get With The Guidelines-Stroke population. *Circulation*. 2017;135(2):128-139. doi:10.1161/CIRCULATIONAHA.116.023336
- Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. *Stroke*. 2010;41(10):2254-2258. doi:10.1161/STROKEAHA.110.592535
- American Heart Association; American Stroke Association. Severity-based stroke triage algorithm for EMS: 2017. [http://www.heart.org/ids/groups/ahaec-public/@wcm/@gwtg/documents/downloadable/ucm\\_498615.pdf](http://www.heart.org/ids/groups/ahaec-public/@wcm/@gwtg/documents/downloadable/ucm_498615.pdf). Accessed July 2, 2018.
- Wheeler HM, Mlynash M, Inoue M, et al. The growth rate of early DWI lesions is highly variable and associated with penumbral salvage and clinical outcomes following endovascular reperfusion. *Int J Stroke*. 2015;10(5):723-729. doi:10.1111/ijss.12436
- Bang OY, Saver JL, Buck BH, et al; UCLA Collateral Investigators. Impact of collateral flow on tissue fate in acute ischaemic stroke. *J Neurol Neurosurg Psychiatry*. 2008;79(6):625-629. doi:10.1136/jnnp.2007.132100
- Bristow MS, Simon JE, Brown RA, et al. MR perfusion and diffusion in acute ischemic stroke: human gray and white matter have different thresholds for infarction. *J Cereb Blood Flow Metab*. 2005;25(10):1280-1287. doi:10.1038/sj.jcbfm.9600135
- Wegener S, Gottschalk B, Jovanovic V, et al; MRI in Acute Stroke Study Group of the German Competence Network Stroke. Transient ischemic attacks before ischemic stroke: preconditioning the human brain? a multicenter magnetic resonance imaging study. *Stroke*. 2004;35(3):616-621. doi:10.1161/01.STR.0000115767.17923.6A
- Rocha M, Jovin TG. Fast versus slow progressors of infarct growth in large vessel occlusion stroke: clinical and research implications. *Stroke*. 2017;48(9):2621-2627. doi:10.1161/STROKEAHA.117.017673
- Albers GW. Late window paradox. *Stroke*. 2018;49(3):768-771. doi:10.1161/STROKEAHA.117.020200
- Hebert D, Lindsay MP, McIntyre A, et al. Canadian stroke best practice recommendations: Stroke rehabilitation practice guidelines, update 2015. *Int J Stroke*. 2016;11(4):459-484. doi:10.1177/1747493016643553

31. McTaggart RA, Ansari SA, Goyal M, et al; Standards and Guidelines Committee of the Society of NeuroInterventional Surgery (SNIS). Initial hospital management of patients with emergent large vessel occlusion (ELVO): report of the standards and guidelines committee of the Society of NeuroInterventional Surgery. *J Neurointerv Surg*. 2017;9(3):316-323. doi:10.1136/neurintsurg-2015-011984
32. Sacks D, Black CM, Cognard C, et al; American Society of Neuroradiology; Canadian Interventional Radiology Association; Cardiovascular and Interventional Radiological Society of Europe; Society for Cardiovascular Angiography and Interventions; Society of Interventional Radiology; Society of NeuroInterventional Surgery; European Society of Minimally Invasive Neurological Therapy; Society of Vascular and Interventional Neurology. Multisociety consensus quality improvement guidelines for intraarterial catheter-directed treatment of acute ischemic stroke, from the American Society of Neuroradiology, Canadian Interventional Radiology Association, Cardiovascular and Interventional Radiological Society of Europe, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, European Society of Minimally Invasive Neurological Therapy, and Society of Vascular and Interventional Neurology. *J Vasc Interv Radiol*. 2013;24(2):151-163. doi:10.1016/j.jvir.2012.11.028
33. Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. *JAMA*. 2014;311(16):1632-1640. doi:10.1001/jama.2014.3203
34. Menon BK, Xu H, Cox M, et al. Components and trends in door to treatment times for endovascular therapy in Get With the Guidelines-Stroke hospitals. *Circulation*. 2019;139(2):169-179. doi:10.1161/CIRCULATIONAHA.118.036701
35. Ovbiagele B, Saver JL. Day-90 acute ischemic stroke outcomes can be derived from early functional activity level. *Cerebrovasc Dis*. 2010;29(1):50-56. doi:10.1159/000255974
36. Zhang Q, Yang Y, Saver JL. Discharge destination after acute hospitalization strongly predicts three month disability outcome in ischemic stroke. *Restor Neurol Neurosci*. 2015;33(5):771-775.
37. Goyal M, Jadhav AP, Bonafe A, et al; SWIFT PRIME Investigators. Analysis of workflow and time to treatment and the effects on outcome in endovascular treatment of acute ischemic stroke: results from the SWIFT PRIME randomized controlled trial. *Radiology*. 2016;279(3):888-897. doi:10.1148/radiol.2016160204

---

### Editor's Note

---

## Endovascular Therapy for Acute Ischemic Stroke Treated in Clinical Practice

Christopher C. Muth, MD

**Five randomized clinical trials**, published in 2015, demonstrated the benefit of endovascular therapy in appropriately selected patients with acute ischemic stroke due to large vessel occlusion, and a subsequent individual patient data meta-analysis of these trials indicated that the benefit associated with endovascular



Related article [page 252](#)

therapy was greater the earlier that endovascular reperfusion was achieved.<sup>1</sup> Since publication of these important trials, the use of endovascular therapy in the United States has significantly increased,<sup>2</sup> and efforts are ongoing to maximize the potential benefits of endovascular therapy for the greatest number of eligible patients possible.

This issue of *JAMA* includes a report from a US nationwide clinical registry—the Get With The Guidelines-Stroke registry—which describes the clinical, technical, and adverse event outcomes in 6756 patients with acute ischemic stroke who underwent endovascular reperfusion therapy in 2015 or 2016 within 8 hours of symptom onset, the generally accepted time window for thrombectomy during the study period.<sup>3</sup> Given the increasing use of endovascular therapy and the highly selected patient population included

in the prior randomized clinical trials, evaluation of outcomes in a large group of patients in routine clinical practice is important.

The study findings generally confirmed the time-benefit relationship previously established in clinical trials, showing that shorter time to endovascular reperfusion therapy was associated with better outcomes and demonstrating generalizability outside of a clinical trial setting. The data may also be useful because they quantify contemporary time-to-treatment estimates for US stroke systems of care and may help inform potential future treatment target times for endovascular therapy.

The findings also suggest the possibility of a nonlinear time-outcome relationship, with more rapid loss of benefit in the first few hours after stroke onset. As indications for endovascular therapy continue to evolve (eg, with the use of perfusion imaging for patient selection), these data may help guide the use of advanced imaging for determining patients' candidacy for endovascular intervention. Future studies will need to consider broader time windows as the use of endovascular therapy expands beyond the time window evaluated in this study.

**Author Affiliations:** *JAMA*, Chicago, Illinois; Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois.

**Corresponding Author:** Christopher C. Muth, MD, *JAMA*, 330 N Wabash Ave, Chicago, IL 60611 ([christopher.muth@jamanetwork.org](mailto:christopher.muth@jamanetwork.org)).

**Conflict of Interest Disclosures:** None reported.

1. Saver JL, Goyal M, van der Lugt A, et al; HERMES Collaborators. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. *JAMA*. 2016;316(12):1279-1288. doi:10.1001/jama.2016.13647

2. Smith EE, Saver JL, Cox M, et al. Increase in endovascular therapy in Get With the Guidelines-Stroke after the publication of pivotal trials. *Circulation*. 2017;136(24):2303-2310.

3. Jahan R, Saver JL, Schwamm LH, et al. Association between time to treatment with endovascular reperfusion therapy and outcomes in patients with acute ischemic stroke treated in clinical practice. *JAMA*. doi:10.1001/jama.2019.8286